Japan approves Wegovy for obesity with narrow eligibility rules

Japan's Ministry of Health, Labour and Welfare has approved Novo Nordisk's Wegovy for obesity, but the clearance is narrower than that single word suggests. The approval, reported on April 10, 2023, limits the once-weekly injection to patients who meet specific body mass index cutoffs and who already have certain health conditions ^[1].

Wegovy is a once-weekly injection of semaglutide, a GLP-1 receptor agonist. It contains the same active ingredient as Novo Nordisk's diabetes treatments Ozempic, an injection, and Rybelsus, a tablet ^[1].

Japan cleared the drug for an indication of "obesity," but it will only be used in "patients with hypertension, dyslipidemia, or type 2 diabetes who have not responded adequately to diet and exercise therapy" ^[1]. Dyslipidemia means unhealthy levels of fats in the blood. In practical terms, a patient must have at least one of those three conditions and must have already tried diet and exercise without enough benefit ^[1].

Patients must also fit one of two BMI categories. The first is a BMI of at least 27 kg/m2 along with at least two obesity-related health disorders. The second is a BMI of at least 35 kg/m2 on its own ^[1].

The result is a label that stacks requirements: a qualifying condition such as high blood pressure, dyslipidemia or type 2 diabetes, plus a BMI threshold that is either lower with more related conditions or higher by itself, plus a prior attempt at diet and exercise ^[1].

Why it matters for patients

Regulatory decisions are country-specific. The criteria Japan's regulator set apply to patients in Japan. They do not change what Wegovy or any other semaglutide product is approved for in the United States, and they do not change how US clinicians prescribe it. Nor does this approval mean the drug is available to everyone in Japan with obesity — the label names specific groups ^[1].

For US readers weighing GLP-1 medications, Japan's approach shows how much a label can vary around a single word like "obesity." A broad indication can come with narrow conditions attached: which patients qualify, what other diagnoses they must have, and how high their BMI must be ^[1]. Anyone comparing access to these drugs across countries is comparing different sets of rules, not the same drug under the same terms.

The approval also restates a detail that is often blurred in everyday conversation: Wegovy, Ozempic and Rybelsus all contain semaglutide, even though they are marketed for different uses ^[1]. Japan's approval covers Wegovy specifically, under the limits described above ^[1].

What happens next

The approval applies to Japan only. When Wegovy will reach Japanese pharmacies, what it will cost there, and whether Novo Nordisk plans to seek a broader label in Japan have not been reported. Whether public insurance in Japan will cover the drug under these criteria has not been disclosed.